HIV Infections
Conditions
Keywords
Drug Therapy, Combination, Zidovudine, Drug Administration Schedule, HIV Protease Inhibitors, CD4 Lymphocyte Count, Indinavir, Delavirdine, Reverse Transcriptase Inhibitors, Anti-HIV Agents, Viral Load
Brief summary
The purpose of this study is to see whether it is better to take delavirdine (DLV) plus indinavir (IDV) plus zidovudine (ZDV) twice a day or three times a day.
Detailed description
Patients are divided into 2 treatment groups; the groups are balanced with respect to viral load. Group A receives ZDV, DLV, and IDV 3 times daily. Group B receives ZDV, DLV, and IDV 2 times daily. Patients are evaluated for changes from baseline in viral load and CD4 cell count.
Interventions
Sponsors
Pharmacia and Upjohn
Study design
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
14 Years to No maximum
Healthy volunteers
No
Inclusion criteria
You may be eligible for this study if you: * Are HIV-positive. * Have a viral load (level of HIV in the blood) of at least 20,000 copies/ml. * Have a CD4 cell count of at least 50 cells/mm3. * Are at least 14 years old (consent of parent or guardian is required if under 18).
Exclusion criteria
You will not be eligible for this study if you: * Have ever taken an anti-HIV drug other than ZDV. * Have taken ZDV for more than 1 month.
Countries
United States
Outcome results
None listed